Mrs Laura Lynn Scrofani-jones, LCSW | |
11990 Jackson St, Clinton, LA 70722-3210 | |
(225) 683-5292 | |
(225) 683-3411 |
Full Name | Mrs Laura Lynn Scrofani-jones |
---|---|
Gender | Female |
Speciality | Social Worker - Clinical |
Location | 11990 Jackson St, Clinton, Louisiana |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1861727349 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
101YM0800X | Counselor - Mental Health | 9370 (South Carolina) | Secondary |
1041C0700X | Social Worker - Clinical | 12184 (Louisiana) | Primary |
Mailing Address | Practice Location Address |
---|---|
Mrs Laura Lynn Scrofani-jones, LCSW Po Box 395, Clinton, LA 70722-0395 Ph: (225) 683-5292 | Mrs Laura Lynn Scrofani-jones, LCSW 11990 Jackson St, Clinton, LA 70722-3210 Ph: (225) 683-5292 |
News Archive
People with stage III colon cancer who regularly eat nuts are at significantly lower risk of cancer recurrence and mortality than those who don't, according to a new, large study led by researchers at Yale Cancer Center.
Today, Intercell AG announced its financial results for Q2 and H1 2010.IXIARO/JESPECT sales increased significantly from EUR 2.4m in Q2 2009 to EUR 5.2m in Q2 2010 Continued focus on growing marketing and sales of product in traveler and military markets
The Case Management Society of America (CMSA) and DMAA: The Care Continuum Alliance (DMAA) are working together to strengthen and define the relationship between health care "case management" and "population health management" interventions.
Transcend Services, Inc., a leading provider of clinical documentation solutions to the U.S. healthcare market, today announced its unaudited financial results for the second quarter ended June 30, 2011.
Golimumab, a new tumour necrosis factor-α (TNF-α) inhibitor reduces the signs and symptoms of rheumatoid arthritis in patients who have previously received any other TNF-α inhibitor, and might be a good option for patients who have inadequate responses to one or two other TNF-α inhibitors, finds an Article published Online first and in this week's edition of The Lancet.
› Verified 5 days ago